Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aspen Pharma Buys Sandoz’s China Operations for $120 Million

publication date: Dec 7, 2023

Aspen Pharmacare of South Africa will expand its China operations by acquiring Sandoz’s China business for $100 million plus $20 million in revenue milestones for the portfolio. In return, Aspen will sell European rights to four anesthetic products to Sandoz for $60 million plus $10 million if sales meet targets. After the agreement closes, Aspen will have rights to Sandostatin, Aclasta and Voriconazole plus a pipeline of products that will be available in China in the medium term. Aspen expects the China products will add $60 million to its revenues, while it will lose $15 million from its European sales. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital